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ABSTRACT
Purpose: Colorectal cancer is the second leading cause of cancer mortality in the United States. Ac-
cording to the National Institute of Statistics in Bulgaria for 2012 there have been 2370 newly di-
agnosed colon cancer and 1664 rectal cancer cases and the total number of registered patients is 
29995. Adding Bevacizumab to chemotherapy in patients with metastatic colorectal cancer im-
proves progression-free survival but yet no predictive markers for patient selection have been de-
scribed and proved in the clinical practice. In our study we examined two plasma biomarkers that 
may correlate with response to first line Bevacizumab containing chemotherapy in patients with 
metastatic colorectal cancer.
Patients and Methods: 54 patients with metastatic colorectal cancer were assigned to first line 5-Fu-
based chemotherapy with/without Bevacizumab. The primary end point was progression-free sur-
vival, with additional determination of response and toxicity. Blood samples were collected at base-
line from all 54 patients prior to initiation of chemotherapy and Bevacizumab. Plasma samples were 
stored at -80º C until analysis at the Immunology Laboratory at the University Hospital “St. Ma-
rina” (Varna, Bulgaria) by a multiple-step sandwich immunoassay Human ELISA VEGF121 and 
VEGF165 kits. 
Results: The median progression-free survival for the group treated with CT/Bev was 8.8 months, 
compared with 5.4 months for the group treated with chemotherapy alone (95% CI, log-rank test P 
=0.003). The corresponding overall response rates were 19.3% and 10.2% respectively (P < 0.05 for 
CT/Bev vs CT).
Conclusion: The addition of Bevacizumab to 5-Fu based chemotherapy improves progression-free 
survival duration for patients with metastatic colorectal cancer. We could not find any association 
between pretreatment plasma levels of VEGF 121 and 165 and worse PFS.
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INTRODUCTION
The development of new blood vessels, 
termed angiogenesis, is a typical hallmark 
of cancer development. Four decades ago, 
angiogenesis was recognized as a therapeutic 
target for blocking cancer growth and 
antiangiogenic therapy showed broad clinical 
activity.1 The most important signaling molecule 
is the vascular endothelial growth factor or 
VEGF – it plays a central role in angiogenesis 
and is frequently highly expressed in cancers. 
Thus clinical efforts to develop antiangiogenic 
therapies have largely focused on inhibiting 
VEGF.2 However not all patients benefit 
from antiangiogenic therapy; the magnitude 
of response to this treatment also varies 
among patients, which makes identification of 
potential predictive biomarkers a crucial point 
in clinical practice.3 Identifying which tumors 
are most sensitive to anti-VEGF therapy would 
improve therapeutic outcome of patients and 
could provide insights into the mechanism of 
resistance to anti-VEGF therapy. 
Multiple VEGF receptors are expressed on 
endothelial cells, including signaling receptor 
tyrosine kinases (VEGFR1 and VEGFR2) and 
the nonsignaling co-receptor Neuropilin-1. It 
is considered that the proangiogenic effect of 
VEGF is mediated predominantly via VEGFR2. 
4,5 Neuropilin-1 binds only the isoform of 
VEGF responsible for pathological angiogenesis 
(VEGF165), and is thus a potential target for 
inhibiting VEGF signaling. VEGF121 is the 
predominant isoform, is considered by some to 
be the most proangiogenic and tumorigenic of 
the VEGF isoforms 6.
In our single center study we compared the 
efficacy of bevacizumab (anti-VEGF antibody) 
plus chemotherapy versus only chemotherapy as 
first line-treatment for patients with metastatic 
colorectal cancer (mCRC).
We tried to improve our understanding of 
the complexity of tumor angiogenesis with the 
evaluation of two serum biomarkers: circulating 
soluble VEGF (121 and 165 isoforms).
PATIENT SELECTION
We conducted a prospective non-
experimental clinical study of 54 patients with 
histologically confirmed metastatic colorectal 
adenocarcinoma stage IV as per AJCC, 7th ed. 
All patients underwent surgery of the primary 
tumor; they had measurable disease as defined 
by the Response Evaluation Criteria in Solid 
Tumors version 1.1 (RECIST 1.1)7 and were 
eligible for Bevacizumab-containing 5-Fu based 
chemotherapy regimens as first line treatment. 
Their ECOG performance status was <2. 
Chemotherapy was performed at the University 
Hospital “St. Marina” and patients were 
subsequently followed for a period of up to 2 
years – first patient was included on 15 February 
2013 until follow up of last patient until 1 August 
2015. Prior to inclusion in our study we obtained 
ICF for collection of biological material (plasma/
serum) from all patients willing to participate. 
Plasma/serum with K2EDTA as 
anticoagulant was collected at baseline. A 
second measurement of plasma/serum markers 
after 3 months (4-6 cycles) was done for 20 
patients. Blood was centrifuged at 1000 g at 4°C 
for 15 minutes and plasma was stored in aliquots 
at -80°C until analysis. Plasma VEGF121 and 
VEGF165 levels were assessed by sandwich ELISA 
immunoassays with ready to use kits according 
to manufacturer's instructions. VEGF121 levels 
were assayed with Human VEGF121 ELISA Kit, 
catalog number CSB-E13709h (Cusabio, China) 
and VEGF165 with Human VEGF165 ELISA Kit, 
catalog number CSB-E13100h (Cusabio, China).
CLINICAL AND PATHOLOGIC 
FEATURES
We collected the following clinical data: 
demographical data (age at initial staging, sex, 
etc), date of surgery, extent of surgery, tumor 
localization and TNM classification, sites of 
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Table 1. Clinical and pathologic baseline patient 
characteristics.
metastatic dissemination, ECOG performance 
status. 
We collected the following pathologic 
data: tumor characteristics – histology, grade 
of differentiation and TNM classification, RAS- 
status determination.
Clinical and pathologic baseline patient 
characteristics are summarized in Table 1.
TREATMENT CHOICE AND DURATION
Patients received a minimum of 3 months 
of treatment. Chemotherapy regimens used are 
summarized in Table 2.
IMAGING ASSESSMENT, RESPONSE 
PATTERNS AND END POINTS 
DETERMINATION
Imaging the disease was performed at 
baseline and tumor response was assessed at 
regular intervals - every 4-6 cycles (3 months) 
for all cycles of CT/Bev till EOT or upon clinical 
symptoms. Imaging consisted of either CT of 
thorax, abdomen (and other areas if needed 
for additional lesion assessment) or PET/CT. 
Evaluation was performed using RECIST 1.1. 
During systemic treatment, disease free survival 
and response rate were assessed. Response was 
defined as either complete response (CR), partial 
response (PR) or stable disease (SD). Patients 
were followed for up to 2 years after start of first 
line treatment, death or August 1, 2015. 
STATISTICAL DESIGN AND ANALYSIS
Descriptive statistics was used. Categorical 
features were summarized with frequencies and 
percentages. Our sample distribution was tested 
for normality with Kolmogorov-Smirnov and we 
used unpaired t-test to compare sample means.
Our statistical analysis included 54 patients 
treated with CT alone or CT/Bev. Our aim 
was to evaluate PFS and potential correlations 
and identification of good responders to 
Bevacizumab-containing treatment. PFS was 
defined as the time from assignment of treatment 
until progression. Survival curves were estimated 
by the Kaplan-Meier method,8 with differences 
assessed by the log-rank test.9 Differences of P < 
0.05 were considered statistically different.
RESULTS
Efficacy
Our experience confirms that the addition 
of Bevacizumab to chemotherapy resulted in 
improvement in progression-free survival which 
remains a good surrogate for measurement 
of overall survival in patients with colorectal 
cancer. Our study demonstrate a significant 
improvement in PFS with the addition of 
Bevacizumab to chemotherapy (95% CI, log-
rank test P =.003). Median PFS was 5.4 months 
(3.44-6.55) with CT versus 8.8 months (5.84-
10.15) with CT/Bev.
 Using the RECIST 1.1 criteria7 for response, 
19.3% of patients treated with CT/Bev achieved 
a confirmed response to therapy (PR+SD) 
compared with 10.5% of patients treated with 
CT alone. Our results – PFS, response rates and 
toxicity profile of Bevacizumab are consistent 




The toxicity profile of Bevacizumab was 
consistent with that documented in previous 
trials.10-12 As we expected all grade adverse 
events were registered at higher frequency in 
Characteristic 5-FU-based CT + Bev (n = 31) 5-FU-based CT (n = 23) 
Age at diagnosis   
    Median 62.5 64.8 
    Range 37-81 59-81 
Distribution by sex, % females 45.1        males 54.9 females 65.2        males 34.8 
Performance status, %   
    0 41.9 49.2 
    1 49.9 44.0 
    2 8.2 5.8 
Disease site   
    Liver, % 70.9 65.4 
    Lung, % 19.4 16.3 
Mutational status of 
KRAS, % 
KRAS WT                              35.4 
KRAS M+                               48.3 
Inadequate for genetic testing 
16.3 
KRAS WT                            59.7 
KRAS M+                           26.08 
Inadequate for genetic testing 
14.2 
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the group of patients, treated with CT/Bev as 
compared to the only chemotherapy group. 
Most frequent AE as expected were nausea and 
vomiting, asthenia, neuropathy, neutropenia and 
thrombocytopenia. The occurrence of any grade 
3 adverse event was greater for the individuals 
treated with the combination CT/Bev compared 
with patients treated with chemotherapy alone 
(49% vs 37%) with neuropathy, hypertension, 
bleeding, and vomiting. No AEs grade 4 were 
registered in our groups of patients.
Biomarker Levels at baseline
Median plasma levels of VEFG 121 were 
201.4 pg/ml (range, 34 pg/ml to 1112 pg/ml) 
Median plasma levels of VEFG 165 were 205 pg/
ml (range, 51 pg/ml to 731 pg/ml). There was no 
significant difference between the pretreatment 
VEGF 121 and VEGF 165 plasma levels in 
patients with stable disease and in patients who 
progressed on therapy (Figure 2). We could not 
detect any therapy benefit for Bevacizumab-
treated patients according to their VEFG 121 
and VEFG 165 pretreatment levels. Even patients 
with higher than median baseline plasma levels 
of both plasma markers showed no clear benefit 
of the addition of Bevacizumab to CT. Changes 
in plasma levels of VEFG 121 and 165 during 
treatment are unreliable because of interference 
by Bevacizumab (data not shown).
Arm Dosage Administration Schedule 
 FOLFOX4 (± Bevacizumab)  Every 14 days 
    Oxaliplatin 85 mg/m2 IV 120 minutes Day 1 
    Leucovorin 200 mg/m2 IV 120 minutes Days 1 + 2 
    Fluorouracil 400 mg/m2 IV bolus, followed by 
    Fluorouracil 600 mg/m2 IV over 22 hours Days 1 + 2 
  ±  Bevacizumab 10 mg/kg 30-90 minutes Day 1 
FOLFIRI (± Bevacizumab)  Every 14 days 
    Irinotecan 180 mg/m2 IV 30-90 minutes Day 1 
    Leucovorin 200 mg/m2 IV 120 minutes Days 1 + 2 
    Fluorouracil 400 mg/m2 IV bolus, followed by 
    Fluorouracil 600 mg/m2 IV over 22 hours Days 1 + 2 
  ±  Bevacizumab 10 mg/kg 30-90 minutes Day 1 
XELOX (± Bevacizumab)  Every 21 days   
    Oxaliplatin 85 mg/m2 IV 120 minutes Day 1 
    Capecitabine 2000-2500 mg/m2 p.o. Day 1 - 14 
  ±     Bevacizumab 15 mg/kg 30-90 minutes Day 1 
Capecitabine ± Bevacizumab  Every 21 days 
    Capecitabine 2000-2500 mg/m2 p.o. Day 1 - 14 
  ±     Bevacizumab 15 mg/kg 30-90 minutes Day 1 
 
Abbreviations: FOLFOX - oxaliplatin, f luorouracil, and leucovorin; FOLFIRI – irinotecan, f luorouracil, and 
leucovorin; XELOX – oxaliplatin, capecitabine; IV – intravenous; p.o. – per os.
Table 2. Treatment regimens
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DISCUSSION
Antiangiogenic therapy with Bevacizumab 
in combination with chemotherapy prolongs 
survival and PFS for patients with metastatic 
colorectal cancer as this has been previously 
reported in clinical trials (13,14). Improvements 
in clinical outcome do not appear to be limited 
to a single chemotherapy regimen. 
There are currently no validated surrogate 
markers of biological activity for anti-
VEGF therapy. The reported mechanism of 
action of Bevacizumab and the potential for 
delayed efficacy had led to the speculation 
that PFS or overall survival may be more 
relevant measures of activity than objective 
response rate. Interestingly, improvements 
in objective response rate and PFS translated 
into better overall survival in patients with 
metastatic colorectal cancer receiving first-line 
chemotherapy plus Bevacizumab (10,11).
Pretreatment levels of circulating VEGF 
have been previously studied as a potential 
biomarker for VEGF-targeted therapy, but 
mainly so far they have been shown to be 
Fig. 1.  Kaplan-Meier estimates of progression-free 
survival (PFS). The median PFS for the group treated with 
CT/Bev was 8.8 months, as compared with 5.4 months for 
the group treated with CT alone (95% CI, log-rank test P 
= .003). 
Fig. 2. Plasma concentration in pg/ml of VEGF 121 
and VEGF 165 isoforms as measured and distributed 
according to response to chemotherapy. Response is 
classified as SD (SD + PR) and PD as no complete response 
were documented.
primarily prognostic rather than predictive 
(15-17).
In our relatively small cohorts of patients, we 
could not find any association between these two 
potential biomarkers – VEGF121 and VEGF165, 
with worse PFS. These data also showed that 
treatment outcome in patients receiving CT/
Bev cannot be predicted by baseline levels of 
VEGF121 and VEGF165.
Given the biological complexity of tumor 
angiogenesis and the non-randomized study 
design, our results should be viewed with caution. 
So far, no serum markers were of significant 
predictive value in our pilot study - the data 
presented here suggest that baseline levels of 
neither VEGF121 nor VEGF165 are predictive 
for outcome on Bevacizumab treatment. Further 
research is warranted to clarify the predictive 
value of these markers.
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